Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Antisoma, a biopharmaceutical company, has reported that Attract-1, the Novartis Phase III trial evaluating ASA404 as a first-line treatment for non-small cell lung cancer, is now enrolling patients in Japan.
Subscribe to our email newsletter
Attract-1 has been enrolling patients in a variety of other countries since it began in April 2008. Extension of the trial to Japan follows the successful completion of a Phase I study evaluating the safety of ASA404 in Japanese lung cancer patients, said Antisoma.
Glyn Edwards, Antisoma’s CEO, said: “We’re pleased that Japanese lung cancer patients can now participate in this key Phase III trial of ASA404. This is an important step towards a potential application to market the drug in Japan.”